ProMIRA is a pharmaceutical company that specializes in the development of drugs for the treatment of cancer. The company was founded in 2015 and is headquartered in the United States. ProMIRA's lead product candidate is a small molecule inhibitor of the protein MDM2, which is overexpressed in many types of cancer. The company is also developing other small molecule inhibitors for the treatment of cancer. ProMIRA has received funding from a number of sources, including venture capital firms and government grants.